BACKGROUND AND OBJECTIVES Based on previous studies revealing acid-suppression medication as a risk factor for food allergy tolerance induction, we aimed to establish the importance of those findings in patients undergoing oral immunotherapy (OIT). MATERIALS AND METHODS, RESULTS We describe a case series of four patients who underwent milk OIT with a concomitant use of proton pump inhibitor (PPI) medication and who developed anaphylaxis after a known, previously tolerated dose of milk. CONCLUSIONS PPIs may act as a cofactor in patients undergoing OIT, triggering adverse reactions, irrespective of the PPI used or the dosage. It would be necessary to separate the administration of drug from food intake.Since OIT is a new form of treatment, long-term adverse events arising from PPI treatment and other possible triggers are still uncertain. Consequently, monitoring of patient must be prolonged over time. Additional investigations on the influence of different drugs in OIT maintenance phase are required.

中文翻译：

---

在接受口服食品免疫疗法的患者的不良反应中，以质子泵抑制剂作为辅助因子进行治疗。

背景与目的基于以往的研究表明，抑酸药物是诱导食物过敏耐受的危险因素，我们的目的是确定这些发现对接受口服免疫疗法（OIT）的患者的重要性。材料和方法，结果我们描述了一个病例系列，其中四例患者在接受牛奶OIT的同时伴有质子泵抑制剂（PPI）药物的使用，并且在已知的先前耐受剂量的牛奶后出现了过敏反应。结论PPI可能在接受OIT的患者中充当辅助因子，引发不良反应，而与使用的PPI或剂量无关。由于OIT是一种新的治疗方法，因此有必要将药物的管理与食物摄入分开。由于PPI治疗引起的长期不良事件以及其他可能的诱因仍是不确定的。因此，必须随时间延长对患者的监视。需要对OIT维持阶段中不同药物的影响进行进一步调查。